Purpose: This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Arms
- Experimental: Treatment (tivantinib)
- Patients receive tivantinib PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
- Assigned Interventions
- Drug: tivantinib
- Given PO
- Other Name: ARQ 197
- Other: laboratory biomarker analysis
- Correlative studies